Gut Talk

Author: Sameer K. Berry, MD, and William D. Chey, MD

Sameer K. Berry, MD, and William D. Chey, MD, host this Healio podcast that provides busy clinicians with quick updates that directly affect their GI practices. Through interviews and candid conversations, they explore how health policy, social media, technology, nutrition, practice management and research impact the field of Gastroenterology. Most importantly, the show also features interviews with patients to add a unique perspective on the topics that matter.
Be a guest on this podcast

Language: en

Genres: Health & Fitness, Life Sciences, Medicine, Science

Contact email: Get it

Feed URL: Get it

iTunes ID: Get it

Get all podcast data

Listen Now...

Incorporating, retaining advanced practice providers in GI practice
Episode 47
Friday, 24 July, 2026

In this episode, hosts Sameer Berry, MD, and William Chey, MD, speak with Sarah Enslin, PA-C, Vivek Kaul, MD, and Amy Stewart, CRNP, about the benefits of introducing advanced practice providers in practice and how to help them succeed. · How can advanced practice providers, or APPs, help overcome access barriers in gastroenterology? 6:54 · How can we effectively onboard APPs? 10:24 · Is ACG's APP Academy for Clinical Excellence accounting for the fact that different specialties and practices have different requirements? 18:21 · What models have worked well for deploying APPs into GI practices? 24:32 · What strategies are most effective for APP retention? 29:07 · How can we improve professional development for APPs? 42:14 We'd love to hear from you! Send your comments/questions to guttalkpodcast@healio.com. Follow us on X @HealioGastro, @sameerkberry and @umfoodoc. Berry and Chey report no financial disclosures. Stewart reports financial relationships with AbbVie, Ardelyx, Celltrion, Cristcot, Eli Lilly & Co, Exact Sciences, Genentech, Johnson & Johnson, Merck, Mindset Health (Nerva), Nestle Health Science, Pfizer, Phathom Pharmaceuticals, Prometheus Laboratories, Regeneron, Salix Pharmaceuticals, Sanofi and Takeda Pharmaceuticals. Healio could not confirm relevant financial disclosures for Enslin and Kaul at the time of publication.